Hanlim Pharm Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-03-14
- Employees
- 251
- Market Cap
- -
- Website
- http://hanlim.com
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
Phase 1
Completed
- Conditions
- Gastric Ulcer
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06642987
- Locations
- 🇰🇷
Seok Gyeong Medical Foundation Central Hospital, Siheung-si, Korea, Republic of
Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Primary HypercholesterolemiaCombined Hyperlipidemia
- Interventions
- Drug: Crecheck Tablet 2.5 mg
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06475872
- Locations
- 🇰🇷
Seok Gyeong Medical Foundation Central Hospital, Gyeonggi-do, Korea, Republic of
Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease
Phase 2
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: PlaceboDrug: Bronpass Tab.
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT06434792
- Locations
- 🇰🇷
Konkuk University School of Medicine, Seoul, Korea, Republic of
Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection
Recruiting
- Conditions
- Reversal of Neuromuscular Blockade
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 1500
- Registration Number
- NCT06246331
- Locations
- 🇰🇷
Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of
An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
Recruiting
- Conditions
- Hypertension
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 4000
- Registration Number
- NCT06214832
- Locations
- 🇰🇷
Seoul song clinic, Seoul, Korea, Republic of
An Observational Study on the Identification of Prescription Patterns of STAFEN Cap
Recruiting
- Conditions
- Mixed Dyslipidemia
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 4000
- Registration Number
- NCT06204380
- Locations
- 🇰🇷
Delphoe Clinic, Gangneung-si, Korea, Republic of
DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy
Completed
- Conditions
- Diabetic Peripheral Neuropathy
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT06191614
- Locations
- 🇰🇷
Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
The Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 3000
- Registration Number
- NCT06188234
- Locations
- 🇰🇷
Cheonan Endo Medical Clinic, Cheonan, Korea, Republic of
Observational Study on the Improvement of Dry Eye Syndrome, Treatment Satisfaction, and Intraocular Tolerance With Diquasol Eye Drops
Recruiting
- Conditions
- Dry Eye Syndrome
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 2000
- Registration Number
- NCT06172530
- Locations
- 🇰🇷
CK St. Mary's Eye Clinic, Seoul, Korea, Republic of
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Recruiting
- Conditions
- Essential Hypertension
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 5000
- Registration Number
- NCT06130124
- Locations
- 🇰🇷
Bundang Seoul University Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath